Waye, M.D.: Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths It’s been a long-standing up belief that screening for colorectal malignancy make a difference mortality from the condition in two methods: by detecting cancers at an early, curable stage and by removing and detecting adenomas.1 Detection of early-stage colorectal cancers has been shown to be associated with a decrease in mortality from colorectal malignancy in screening trials.2-4 However, an adenomatous polyp is a more common neoplastic acquiring about endoscopic screening. We previously reported that colonoscopic polypectomy in the National Polyp Research cohort reduced the incidence of colorectal malignancy.5 An important question is whether the cancers avoided by colonoscopic polypectomy in the cohort were those that got the potential to cause death.Multivariate logistic regression was used to regulate for the baseline factors. All statistical analyses had been performed with the use of SAS software, version 9.2. Based on the results of the GeparDuo study ,16 we assumed that the rate of pathological complete response with epirubicin and cyclophosphamide accompanied by docetaxel would be 14 percent; we expected that the rate of pathological complete response with epirubicin and cyclophosphamide followed by docetaxel plus bevacizumab will be 18.9 percent .